Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTZ-232 in advanced/metastatic colorectal cancer and other solid tumors
NCT07878988Phase 1Recruiting
- Start
- Oct 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
Phase 1, open-label trial of LTZ-232 in colorectal cancer (CRC) and solid tumor (3 arms). Primary endpoint: Adverse Events at 24 months. Started Oct 2026; status: recruiting.
02
Drugs
LTZ-232
03
Conditions
colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT07878988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07878988.